Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

XERIS PHARMACEUTICALS INC (XERS)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-20Dec-31-19Dec-31-18Dec-31-17Dec-31-16
   10-K10-K10-K10-KS-1
Revenues  20.21.60.00.00.1
            Revenue growth  1138.8% -100.0%-69.8% 
Cost of goods sold  9.31.6-2.40.00.0
Gross profit  10.80.02.40.00.0
            Gross margin  53.7%1.5% 75.0%84.9%
Selling, general and administrative   [+]73.763.121.18.04.1
Research and development  20.960.440.720.210.2
Other operating expenses  -0.3-1.1 -1.5-1.0
EBITDA   [+]-82.1-121.3-59.0-26.4-13.1
            EBITDA margin  -407.2%-7455.6% -165025.0%-24745.3%
Depreciation and amortization  1.51.10.30.20.1
EBIT   [+]-83.5-122.4-59.3-26.6-13.2
            EBIT margin  -414.5%-7521.8% -166431.3%-24964.2%
Interest expense, net   [+]7.74.40.9-0.10.0
Other income (expense), net   [+]0.11.20.20.00.0
Pre-tax income  -91.1-125.6-60.1-26.6-13.2
Income taxes  0.10.50.00.00.0
            Tax rate    0.0%0.0%0.0%
Net income  -91.3-126.0-60.1-26.6-13.2
            Net margin  -452.7%-7746.7% -165962.5%-24922.6%
   
Basic EPS   [+]($2.14)($4.83)($4.99)($13.09)($7.17)
Diluted EPS   [+]($2.14)($4.83)($4.99)($13.09)($7.17)
   
Shares outstanding (basic)   [+]42.626.112.02.01.8
Shares outstanding (diluted)   [+]42.626.112.02.01.8
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy